Perspective Therapeutics (CATX) Change in Accured Expenses (2016 - 2026)

Perspective Therapeutics' Change in Accured Expenses history spans 17 years, with the latest figure at -$4.2 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 64.19% to -$4.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.5 million, a 824.64% decrease, with the full-year FY2025 number at $147000.0, down 92.22% from a year prior.
  • Change in Accured Expenses hit -$4.2 million in Q1 2026 for Perspective Therapeutics, down from -$1.1 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CATX hit a ceiling of $15.7 million in Q3 2024 and a floor of -$13.0 million in Q4 2024.
  • Historically, Change in Accured Expenses has averaged $90647.1 across 5 years, with a median of $117000.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: soared 3725.0% in 2022 and later crashed 678.32% in 2024.
  • Tracing CATX's Change in Accured Expenses over 5 years: stood at $573000.0 in 2022, then soared by 293.72% to $2.3 million in 2023, then crashed by 678.32% to -$13.0 million in 2024, then soared by 91.68% to -$1.1 million in 2025, then crashed by 287.94% to -$4.2 million in 2026.
  • Business Quant data shows Change in Accured Expenses for CATX at -$4.2 million in Q1 2026, -$1.1 million in Q4 2025, and $1.7 million in Q3 2025.